Guest: James Taylor In this episode of Boba & Biotech, Armon sits down with James Taylor, co-founder of Precision NanoSystems, for a candid conversation about building a platform technology for nanoparticle-delivered RNA medicines from a PhD project into an 11-year journey that ended in an acquisition by Danaher Corporation, a leading global life sciences and diagnostics healthcare company.  They cover the early grind of bootstrapping with non-dilutive grants, why it took five years to raise a Series A, and the case for staying a tools company even as the "sexier" path to therapeutics beckoned. Taylor opens up about a near-death experience scaling the sales team, the hard lessons of building a channel as a technical founder, and why boards don't run companies, management does. They also dig into building in Vancouver V.S. the US, the tension between royalty and per-unit business models, and what he'd change about how the industry communicates its impact to the world. James Taylor is the Co-Founder and former CEO of Precision NanoSystems (PNI), a Vancouver-based life science tools company specializing in lipid nanoparticle platform technology. He holds a B.A.Sc. in engineering physics and a Ph.D. in genetics from the University of British Columbia (UBC). After 11 years building PNI, James led its acquisition by Danaher, where it was integrated into Cytiva's Life Sciences portfolio. Links Armon’s LinkedIn - https://www.linkedin.com/in/armonsharei/   James’ LinkedIn - https://www.linkedin.com/in/taylorrobertjames/  Credits Hosted by Armon Sharei, PhD Research by Julie Kim, MBA Produced by David Woje, Woje Productions, Andressa Carroll, Portal Edited and mixed by David Woje 

Guest: Jason Kelly In this episode of Boba & Biotech, Armon sits down with Jason Kelly, co-founder and CEO of Ginkgo Bioworks, for a conversation about what it takes to build a biotech company from scratch when no one will fund you, why platform business models in biotech are harder than they look, and where he thinks the biggest opportunity in biotech history is hiding. They cover how Ginkgo got started on grants and stubbornness out of MIT, why Jason was deliberate about protecting voting control through IPO, the case for autonomous labs replacing manual bench science, and why longevity and wellness may dwarf everything the industry has built so far. Plus why biotech is still waiting for its YC moment — the infrastructure that would make it as easy for a PhD scientist to start a company as it is for a CS undergrad. Jason Kelly is co-founder and CEO of Ginkgo Bioworks, a publicly traded synthetic biology company he has led since founding it out of MIT in 2008. He holds a BS in chemical engineering and a PhD in bioengineering, both from MIT. Links Armon’s LinkedIn - https://www.linkedin.com/in/armonsharei/   Jason’s LinkedIn - https://www.linkedin.com/in/jrkelly2/  Credits Hosted by Armon Sharei, PhD Research by Julie Kim, MBA Produced by  David Woje, Woje Productions, Andressa Carroll, Portal Edited and mixed by David Woje of Pinwheel 

In the pilot episode of Boba & Biotech, I try out a homemade milk tea with my long time friend and colleague, Shirley Mao. The goal of this episode is to invite listeners into my world - inside and outside of work - and to share the vision behind this brand-new podcast. It's also the fastest way to figure out if I’m boring or insufferable :) From an early interest in math and science, to Stanford, MIT, and the leap from academia into entrepreneurship, the conversation traces what it really takes to turn discovery into real-world impact. We unpack the highs and lows of founding the first company, SQZ Biotech - from early scientific validation and a pivotal Roche partnership to hard-earned leadership lessons along the way.  We also chat about why biotech’s public image misses the mark, how jaded leadership can emerge, and why human clinical translation, not discovery, is the hardest and most important part of the journey. Links mentioned: #cellstories Portal Connect with Armon Connect with Shirley Credits: Hosted by Armon Sharei, PhD Research by Andressa Carroll, Portal  and Shirley Mao, rvnway.com  Produced by Arielle Nissenblatt of Pinwheel, Andressa Carroll of Portal  Edited and mixed by David Woje of Pinwheel 

Biotech has a PR problem. It's messy, complex, and hard to understand from the outside looking in. That's why I'm starting Boba & Biotech. I’m Armon Sharei. You might know me from my cell cartoons on LinkedIn. I was born in California, grew up in Iran and Dubai, and somehow ended up spending most of my life thinking about cells. In this intro episode, I'll lay out my career - how I got to where I am today. Hint: I’m a chemical engineer by training and during my PhD, my colleagues and I accidentally discovered something that led to my first company: SQZ Biotech SQZ went on to operate for ten years. We raised about $400 million, partnered with Roche, went public in 2020, and tried to create a new class of cancer therapies.  Now, I'm the founder and CEO of Portal - a next-gen version of what SQZ had started. Today, we have over 100 customers, a growing team, and support from DARPA to democratize access to next gen cell therapies.  I also proudly sustain a near daily boba habit. I ALSO believe strongly that if you make a difference through science, that difference is irreversible. No one can ever take back a cure to a disease. And that’s why this podcast exists.  Boba & Biotech is about giving biotech a real face. It’s about scientists, founders, investors, pharma leaders, and the people in between - talking without the sanitized bullshit about how this industry actually works. We’ll talk about science, clinical trials, finance, and all the other ingredients that go into making a drug. More info: About me About Portal

Guest: Mark Dempster In this episode of Boba & Biotech, Armon sits down with Mark Dempster, Co-Head of Healthcare Investment Banking at Stifel, to pull back the curtain on what biotech bankers actually do and why it matters more than most founders realize. They cover the public vs. private financing divide, why the stigma around banks helping with private rounds exists and whether it still makes sense, and what founders consistently get wrong when they go public for the first time. Mark also shares his honest take on why generalist investors stay skittish about biotech, what the FDA environment means for the ecosystem right now, and why data ultimately trumps everything else when it comes to predicting who succeeds. Mark Dempster is Co-Head of Healthcare Investment Banking at Stifel, where he has focused on biotechnology and specialty pharma for over 25 years. He has held roles at JP Morgan and Bank of America Securities, and has been with Stifel since 2010. He holds an MBA from the University of Michigan and a B.S. in Finance from Bradley University. Links Armon’s LinkedIn - https://www.linkedin.com/in/armonsharei/   Mark’s LinkedIn - https://www.linkedin.com/in/mark-dempster-22816b/  Credits Hosted by Armon Sharei, PhD Research by Julie Kim, MBA Produced by Arielle Nisseblatt of Pinwheel, Andressa Carroll, Portal Edited and mixed by David Woje

Guest: William Pao  In this episode of Boba & Biotech, Armon sits down with William Pao, a physician-scientist who has run oncology R&D at Roche, served as Chief Development Officer at Pfizer, and is now CEO and Co-Founder of Revelio Therapeutics. Few people have seen drug development from as many angles. They get into the real economics behind why a single molecule can cost $600M to advance, what it actually feels like to kill a program you believe in, and why the jump from pharma to biotech is more disorienting than most people expect. Plus: where AI in drug development is genuinely useful, where it isn't, and what the Paxlovid story reveals about why institutional memory matters more than anyone talks about. William Pao is a physician-scientist whose career has spanned academia, industry, and biotech. As a faculty member at Memorial Sloan-Kettering and Vanderbilt University, he was a practicing oncologist recognized for ground-breaking work in targeted cancer therapeutics and personalized medicine. Through executive leadership at Roche and Pfizer, he oversaw the development of molecules now approved across cancer, rare diseases, ophthalmology, infectious diseases, neuroscience, and immunology. He is currently CEO and Co-Founder of Revelio Therapeutics, co-founder of MyCancerGenome, and author of Breakthrough: The Quest for Life-Changing Medicines. He holds an undergraduate degree from Harvard and an M.D. and Ph.D. from Yale. Links Armon’s LinkedIn - https://www.linkedin.com/in/armonsharei/   William’s LinkedIn - https://www.linkedin.com/in/william-pao-md-phd-40719295/   William’s book - https://breakthroughbypao.com/  Credits Hosted by Armon Sharei, PhD Research by Julie Kim, MBA Produced by Arielle Nisseblatt of Pinwheel, Andressa Carroll, Portal Edited and mixed by David Woje

Guest:Sophia Lugo In this episode of Boba & Biotech, Sophia Lugo and I grab some delicious boba teas to explore her unconventional path into biotech and the realities of building a company at the frontier of genetic medicine. From her early experiences across Harvard, China, and the Gates Foundation to co-founding Radar during her time at Stanford, Sophia shares how urgency, ambition, and a belief in personal agency shaped her journey. She also discusses Radar’s progress, including its mission to solve targeted mRNA delivery and its next milestone of translating in vitro results into in vivo success. The conversation also dives into a critique of the biotech industry - from fundraising as a sales-driven process to the dynamics that shape founder ownership, culture, and exit opportunities. Sophia reflects on a near-death moment early in Radar’s life, the lessons it taught her, and why she believes many of biotech’s constraints, whether cultural or regulatory, are more flexible than they appear. Sophia Lugo is CEO, Chairman, and Co-Founder at Radar Therapeutics, a company enabling precise in vivo genetic medicines, the first company to be able to selectively activate an mRNA therapeutic only in exact cell types of interest. For her work at Radar, Sophia has received the 2024 Biocom Catalyst Award celebrating top professionals under 40 disrupting the life sciences industry. She received her Bachelor’s from Harvard University, Masters from Tsinghua University, and MBA from Stanford University. Links Armon’s LinkedIn - https://www.linkedin.com/in/armonsharei/   Sophia’s LinkedIn - https://www.linkedin.com/in/sophia-lugo-6b8091123/  Radar Therapeutics: https://www.radartx.bio/   Credits Hosted by Armon Sharei, PhD Research by Julie Kim, MBA Produced by Arielle Nisseblatt of Pinwheel, Andressa Carroll, Portal Edited and mixed by David Woje of Pinwheel 

Guest:  Adam Jenkins What actually makes or breaks a biotech startup - and why is it rarely the science? In this episode of Boba & Biotech, Adam Jenkins and I enjoy some delicious grapefruit-coconut sago from Heytea while we discuss the hidden dynamics shaping today’s biotech ecosystem. From the inside workings of incubators like BioLabs and LabCentral to the uncomfortable truth about “zombie” startups, this conversation pulls back the curtain on what really happens between breakthrough science and company success. Along the way, Adam shares hard-earned insights from years of evaluating and advising early-stage companies, revealing why culture trumps data, why your first hires matter more than your pitch deck, and why taking VC money too early might be your biggest mistake. If you’re a founder, operator, or investor navigating biotech, this episode is equal parts reality check and roadmap. Adam Jenkins is the regional site director for BioLabs, where he manages sites across Boston, Cambridge, Vermont, and Toronto. BioLabs is a global innovation infrastructure company creating the physical and community backbone that powers life science discovery worldwide. Prior to BioLabs Adam worked at Biogen, a global biotech focused on neurology, where he headed their data science teams and helped lead their portfolio strategy. He holds a PhD in genetics from Boston College and an MBA from Indiana University. Links Armon’s LinkedIn - https://www.linkedin.com/in/armonsharei/   Adam’s LinkedIn - https://www.linkedin.com/in/adammjenks/ Biolabs: https://www.biolabs.io/  Credits Hosted by Armon Sharei, PhD Research by Julie Kim, MBA Produced by Arielle Nisseblatt of Pinwheel, Andressa Carroll, Portal Edited and mixed by David Woje of Pinwheel

Guest: Klavs F. Jensen  In this episode of Boba & Biotech, I sit down with Klavs Jensen - professor at MIT and former chair of its chemical engineering department - to explore a deceptively simple question: why do some scientific breakthroughs become companies while others never leave the lab? As we unpack the messy journey from academic discovery to startup, Klavs tries his first-ever boba tea, a refreshing mango green tea (sans sugar!) - while sharing candid insights from decades at the intersection of academia, industry, and entrepreneurship. Our conversation dives into the often-misunderstood relationship between universities, startups, and large companies. Klavs explains why many promising ideas are too early for startups, why incremental technologies struggle to displace existing infrastructure, and why timing, talent, and market forces can matter just as much as the science itself. We also explore the human side of innovation: why the skills required to finish a PhD are very different from those needed to build and run a company, and what makes innovation ecosystems like MIT so uniquely effective. Klavs Jensen is the Warren K. Lewis Professor of Chemical Engineering, Professor of Materials Science and Engineering at MIT. He received an MS in chemical engineering at the Technical University of Denmark in 1976 and a PhD in chemical engineering from the University of Wisconsin in 1980. His work can be found in more than 490 journal articles, 180 conference presentations, and 63 US patents. He serves as the inaugural editor-in-chief of the Royal Society of Chemistry’s journal, Reaction Chemistry and Engineering. Links Armon’s LinkedIn - https://www.linkedin.com/in/armonsharei/   Klavs’ LinkedIn - https://www.linkedin.com/in/klavs-jensen-381995a/  Credits Hosted by Armon Sharei, PhD Research by Julie Kim, MBA Produced by Arielle Nisseblatt of Pinwheel, Andressa Carroll, Portal Edited and mixed by David Woje of Pinwheel

Guest: Soufiane AboulhoudaIn this episode of Boba & Biotech, over matching brown sugar milk teas (great minds, same taste), Souf Aboulhouda, co-founder of Nucleate, and I trace his journey from growing up between France, England, and California to pursuing a PhD in the Church Lab at Harvard - where he first stumbled into the world of biotech startups after watching labmates pitch to investors.  What began as a personal crash course in company formation through the Harvard Biotech Club evolved into Nucleate: a global community now spanning ~40 cities and hundreds of universities. Along the way, the mission expanded from simply launching companies to building people - creating a dynamic talent network that helps scientists explore entrepreneurship, pressure-test cofounders, and find meaningful roles beyond the narrow “CEO or bust” narrative. The conversation dives deep into what actually separates biotech from tech: longer timelines, higher failure rates, capital intensity, and the need for pattern recognition that only experience can buy. We unpack why young founders sometimes outperform seasoned veterans and where they stumble , the cultural problem of investor non-candor, and the widening gap between top hubs like Boston/SF and emerging ecosystems. If he had a magic wand? Compress 15-year product roadmaps into one year and cut clinical costs by 10×, unlocking a future where biology innovation moves as fast as its ambition. Soufiane Aboulhouda received his BS from the University of California, Santa Cruz, has worked at the University of California, San Francisco, and received his PhD from Harvard University in the lab of George Church at the Wyss Institute. His thesis research focused on developing pooled in vivo functional genomics tools to interrogate the biology of cell trafficking to enhance solid tumor homing of immune cells. Soufiane is the co-founder and CEO of Nucleate, and has previously served as the President of the GSAS Harvard Biotech Club. Links Armon’s LinkedIn - https://www.linkedin.com/in/armonsharei/   Souf’s LinkedIn - https://www.linkedin.com/in/soufiane-ab/  Nucleate - https://nucleate.org/  Credits Hosted by Armon Sharei, PhD Research by Julie Kim, MBA Produced by Arielle Nisseblatt of Pinwheel  Edited and mixed by David Woje of Pinwheel 

Guest: Ileana Pirozzi  In this episode of Boba & Biotech, I grab a delicious mango-coconut sago with Ileana Pirozzi, a former biotech investor who’s stepping off the venture sidelines and into the founder seat. From growing up in Italy to studying biomedical engineering at Stanford and working at NASA, Ileana shares how venture capital became a crash course in scientific rigor and why it ultimately felt too distant from real impact. The conversation pulls back the curtain on how VC decisions actually get made: why “no” is so hard to say, how fund dynamics and internal politics shape outcomes, and why most firms prefer to follow rather than lead. They dig into what VCs often miss when judging founders, debate generalist versus specialist investors, and call out overrated and underrated trends. The episode closes with a look at what could truly unlock the next wave of clinical impact: rethinking how clinical trials are designed and run. Ileana Pirozzi is the Head of Healthcare Ventures at Lingotto Innovation in New York City, where she leads early-stage investments in technologies at the intersection of healthcare, life sciences, and frontier engineering. Her work focuses on identifying and backing the next generation of companies redefining diagnoses, treatment and delivery of care. Ileana holds a PhD in Bioengineering and Medical Engineering from Stanford University and a BSc from Brown University. Links Armon’s LinkedIn - https://www.linkedin.com/in/armonsharei/  Ileana’s LinkedIn - https://www.linkedin.com/in/ileanapirozzi/  Lingotto Innovation: https://www.lingotto.com/  Credits Hosted by Armon Sharei, PhD Research by Julie Kim, MBA Produced by Arielle Nisseblatt of Pinwheel, Shirley Mao, rvnway.com  Edited and mixed by David Woje of Pinwheel 

In this episode of Boba & Biotech, I go for a tasty brown sugar milk tea with Martin Madaus, former CEO of one of the biggest technology providers in our field, Millipore, for a wide-ranging conversation on what actually creates value in life sciences. Martin traces his unconventional path from veterinary medicine to global leadership roles across pharma, diagnostics, and life science tools, and shares hard-earned perspective on platform businesses versus therapeutics, why tool companies often struggle with adoption, and when M&A truly makes sense. He pushes back on the idea that therapeutics are intellectually “superior” to tools and highlights underappreciated technologies like MRD testing and spatial proteomics. Martin also makes a forceful case for moving beyond animal testing in favor of organ-on-chip models. The episode closes with a look at where real clinical impact may come next - from cell therapies to emerging innovation out of China. Martin Madaus is a seasoned public-company CEO, who has led and advised diagnostics and life science tools companies for decades, including serving as Chairman and CEO of Ortho Clinical Diagnostics and as President, Chairman, and CEO of Millipore Corporation, which he led through its $7.2 billion sale to Merck KGaA. Earlier in his career, he was CEO of Roche Diagnostics North America. Dr. Madaus holds a DVM from the University of Munich and a Ph.D. from the Veterinary University of Hannover. Links Armon’s LinkedIn - https://www.linkedin.com/in/armonsharei/  Martin’s LinkedIn - https://www.linkedin.com/in/martin-madaus-3baaa728/  Credits Hosted by Armon Sharei, PhD Research by Julie Kim, MBA Produced by Arielle Nissenblatt of Pinwheel, Carolyn Corbet of Portal  Edited and mixed by David Woje of Pinwheel